UCSF doses first patient in triple combination clinical trial of OncoSec’s TAVO, Epacadostat and KEYTRUDA

Image: UCSF has dosed first patient in triple combination clinical trial of OncoSec’s TAVO, Epacadostat and KEYTRUDA to treat unresectable squamous cell head and neck cancer. Photo: courtesy of PublicDomainPictures / Pixabay.